Development of a bioassay for anti tumor activity of biological response modifiers of the reticuloendothelial stimulant class: reproducibility of the bioassay.
Intravenously administered DiLuzio glucan, Wellcome C. parvum, and Glaxo BCG caused dose dependent increases in the tumor cell loss from the lungs of C57BL/6J and DBA/2J mice challenged respectively with intravenous 125IuDR labelled B16 or T 1699 mammary carcinoma cells. The results were reproducible with respect to the optimal doses and the magnitudes and shapes of the dose response curves.